Please select the outcome measures that correspond to the clinical trial below.
Title: LimPrOn: Limburg Pre-eclampsia Investigation
Brief Summary: Background:

Multiple adaptations at the cardiovascular system occurs during pregnancy. In the pregnancy condition pre-eclampsia (PE), this adaptations are abnormal. Five to eight percent of all pregnant women worldwide will develop PE.

PE is a pregnancy condition which is characterized with a high blood pressure (\>140/90 mm Hg) and the occurrence of proteinuria (\>3g/dl/24h) after 20 weeks of gestation. When untreated, this condition can have severe complications for both mother and child. It's important to monitor women with a high risk for developing PE for an early detection and treatment of this condition.

For this reason, a multicenter study is set up with the following applications:

1. NICCOMO and Maternal Venous Doppler Echography: impedance cardiograph and an echography of the heart and veins.
2. Maltron: bio-electronic impedance analyze
3. Remote monitoring of the high risk patients to become a more intensive follow-up

Number of inclusions: 2000 pregnant women from the prenatal consultations of eight different hospitals:


Options:
A: Niccomo measurement (10 weeks of pregnancy); Niccomo measurement (20 weeks of pregnancy); Systolic and Diastolic Blood pressure monitoring (10 weeks of pregnancy); Systolic and Diastolic Blood pressure monitoring (20 weeks of pregnancy); a maternal Venous Doppler Echochraphy (10 weeks of pregnancy); Maltron measurement (10 weeks of pregnancy); a maternal Venous Doppler Echochraphy (20 weeks of pregnancy); Maltron measurement (20 weeks of pregnancy); Activity tracker (10 weeks of pregnancy); Weight (10 weeks of pregnancy); Activity tracker (20 weeks of pregnancy); Weight (20 weeks of pregnancy)
B: Gestational age (GA) (Throug study completion, from the first contact with the gynaecologist (after fertilization) untill 34 weeks of gestation.); hospitalization (From 32 weeks of gestation until 34 weeks of gestation); Changes in CV physiological parameters - electrocardiogram (ECT) with Doppler ultrasonography (Month 3 to month 9); changes in CV physiological parameters - impedance cardiography (Month 3 to month 9); changes in CV physiological parameters - bio impedance (Month 3 to month 9); Arterial parameters - pulse transit time (Month 3 to month 9); Arterial parameters - pulsatility index (Month 3 to month 9); Arterial parameters - resistivity index of the left and right arcuate arteries (Month 3 to month 9); venous parameters - venous pulse transit time of the hepatic and left and right renal veins (Month 3 to month 9); venous parameters - hepatic vein impedance index (Month 3 to month 9); venous parameters - left and right renal interlobar vein impedance indices (Month 3 to month 9); systolic blood pressure (Month 3 to month 9); diastolic blood pressure (Month 3 to month 9); Mean arterial blood pressure (Month 3 to month 9); Total body water (Month 3 to month 9); extracellular water (Month 3 to month 9); intracellular water (Month 3 to month 9); ECW/ICW ratio (Month 3 to month 9); stroke volume (Month 3 to month 9); hear rate (beats/min) (Month 3 to month 9); cardiac output (l/min) (Month 3 to month 9); velocity index (1/1,000/s) (Month 3 to month 9); acceleration index (1/100/s²) (Month 3 to month 9); total peripheral resistance (dyn·s·cm-5) (Month 3 to month 9)
C: The primary maternal outcome measure was the number of women having any episode of severe hypertension (BP ³ 170/110mmHg).
D: Recruitment rate (6 months); Retention rate (Till the follow-up period (from 20 weeks to until delivery or termination of the pregnancy) ends); Adherence to protocol (compliance) (5 months); Acceptability of the device (5 months); Acceptability of the BP measurement (5 months)

Answer: A